Apogenix receives additional BMBF grant to develop APG101
APG101, a first-in-class, fully human protein is an inhibitor of the CD95 ligand (CD95L). The company will use the proceeds to develop APG101, and for the production of
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.